EMICIZUMAB
-
CHS Submission to the Canadian Agency for Drugs and Technologies in Health (CADTH) on Hemlibra
Montreal, July 21, 2020 – The Canadian Hemophilia Society has in recent days made submissions to both CADTH (Canadian Agency for Drugs and Technologies in...
-
Dangerously high FIX levels reported in hemophilia B gene therapy
Montreal – June 29, 2020 – During the question-and-answer period of a session on gene therapy during the World Federation of Hemophilia’s virtual summit (June...
-
Patient-reported outcomes via MyCBDR and PROBE: essential to patient advocacy
Montreal, April 17, 2020 – In recent years, the creation of electronic tools that allow people with hemophilia (PwH) to report their health outcomes to...
-
No emicizumab this year for non-inhibitor patients
Montreal, April 17, 2020 – The Canadian Hemophilia Society (CHS) has learned that emicizumab (Hemlibra) will not become available for those with hemophilia A without...